Vivimed Labs gets approval for 6 products

Drugmaker Vivimed Labs has received approval from Uzbekistan for three ophthalmic products and an equal number of oral liquid suspension products that are made at the company’s facilities in Hyderabad.

These six approvals “mark yet another significant milestone for increasing exports of Vivimed’s own brands to multiple countries,” CEO Ramesh Krishnamurthy said. The company planned to launch at least 10 products in the second half of this fiscal.

A release said the three ophthalmic products approved are Dorzolamide drops 5ml (brand name Dorzoviv); Moxifloxacin drops 5ml (Moxsiviv); and Ofloxacin drops 5ml (Zenofloks), made at the company’s sterile ophthalmic facility here.

The three oral liquid suspension products, from its PICS and Health Canada-approved site here, that have been approved are Ambroxol Hydrochloride syrup 15mg/5ml100ml (Ambro Kid); Salbutamol sulphate, Bromhexine HCI, Guaifenesin, Menthol Expectorant (Asko); and Terbutaline sulphate, Bromhexine HCI, Guaifenesin, Menthol expectorant (Broximed).

This article is closed for comments.
Please Email the Editor

Printable version | Jan 21, 2021 2:29:41 AM |

Next Story